TOG Review (RCOG Journal)
MRCOG Part 2
Subfertility and Reproductive Medicine
WHO type 1 anovulation
Key Statistics
- 30% — Secondary amenorrhoea due to HA
- BMI ≥18.5 — Min. BMI before OI in HA
- 75 IU — Starting hMG dose
Don't-miss facts
-
HH may present overweight/obese (unlike lean/low-weight HA) – do not assume low BMI in all type 1 anovulation
-
AMH is unreliable for ovarian reserve assessment in HH/HA (can be suppressed or falsely PCOS-like) – response to gonadotrophin stimulation is the best test
-
HA is a diagnosis of exclusion – brain MRI indicated if headache, visual/thirst/urination change, lateralising signs, or pituitary hormone excess/deficiency features
-
Do not use combined pill solely to restore menses/bone density in HA – masks return of ovarian function; use transdermal estrogen + cyclic progestin instead
-
OI in HA only once BMI ≥18.5 and energy balance optimised – reduces fetal loss/SGA/preterm birth/caesarean risk
-
hMG (not FSH alone) is preferred for type 1 anovulation OI – FSH alone in LH-deplete women gives worse follicular growth/ovulation rates
-
Pulsatile GnRH pumps are not available for therapeutic use in the UK, despite favourable ovulation/pregnancy/multiple- pregnancy rates
-
CBT achieved 87.5% vs 25% ovarian activity vs observation in a small HA RCT – a low-harm option to discuss
Type 1 vs PCOS at a glance
Type 1 (HH/HA/HP): FSH↓ LH↓ estradiol↓ thin endometrium, small/multicystic ovaries
PCOS: FSH normal, LH normal/high, AMH high, thick endometrium, polycystic/high-volume ovaries
Abbreviation Key
- WHO — World Health Organization KNDy
- neurons — kisspeptin-neurokinin B-dynorphin neurons
- HH — hypogonadotrophic hypogonadism
- hMG — human menopausal gonadotrophin
- HA — hypothalamic amenorrhoea
- IVF — in vitro fertilisation
- HP — hypopituitarism
- HRT — hormone replacement therapy
- HPO axis — hypothalamo–pituitary–ovarian axis
- CBT — cognitive behavioural therapy
- GnRH — gonadotrophin-releasing hormone
- DXA — dual-energy X-ray absorptiometry
- FSH — follicle-stimulating hormone
- OI — ovulation induction
- LH — luteinising hormone
- hCG — human chorionic gonadotrophin
- AMH — anti-müllerian hormone
- OHSS — ovarian hyperstimulation syndrome
- PCOS — polycystic ovary syndrome
Source: Talaulikar V, Yasmin E. WHO type 1 anovulation: an update on diagnosis, management and implications for long-term health. The Obstetrician & Gynaecologist 2020;22:178–190. doi:10.1111/tog.12665
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).